New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Lexeo Therapeutics

Contributing Author

Recent Articles by Lexeo Therapeutics

Jan-27	Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics LXEO GlobeNewswire
Jan-12	Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy LXEO GlobeNewswire
Jan-08	Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy LXEO GlobeNewswire
Dec-22	Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference LXEO GlobeNewswire
Dec-04	Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum LXEO GlobeNewswire
Nov-05	Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
Oct-20	Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering LXEO GlobeNewswire
Oct-16	Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement LXEO GlobeNewswire
Oct-16	Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants LXEO GlobeNewswire
Oct-07	Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy LXEO GlobeNewswire
Aug-14	Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
Jul-07	Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia LXEO GlobeNewswire
Jun-24	Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics LXEO GlobeNewswire
May-27	Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases LXEO GlobeNewswire
May-12	Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
May-01	Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting LXEO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.